Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANTE duration of anti-PD-1 therapy in metastatic melanoma
2017-002435-42Phase 4Unknown
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- May 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pembrolizumab and nivolumab in melanoma (2 arms), sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2017-002435-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002435-42.